{
    "hands_on_practices": [
        {
            "introduction": "The Prescription Drug User Fee Act (PDUFA) review clock is the fundamental metronome of the drug approval process, setting the target date for an FDA decision. However, this clock is not immutable; it can be adjusted based on events during the review cycle. This exercise  provides a practical application of these rules by asking you to calculate a new goal date after the submission of a \"major amendment,\" a critical skill for accurately forecasting and managing regulatory timelines.",
            "id": "5052842",
            "problem": "A sponsor submits a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) and is granted Priority Review under the Prescription Drug User Fee Act (PDUFA). Under Priority Review, the FDA’s target action goal date is set at $6$ months from the date of filing acceptance (that is, the start of the review clock at $t = 0$ months). At $t = 4$ months into the review, the sponsor submits a major amendment containing substantial new clinical data. The FDA determines that the amendment is a “major amendment” and exercises its discretion to extend the review clock by $3$ months to allow adequate time to review the new information.\n\nStarting from foundational, well-accepted facts that:\n- Priority Review sets an initial action goal date at $6$ months from filing acceptance, and\n- a major amendment permits the FDA to extend the review clock by up to $3$ months,\n\nderive the new action goal date as a single time interval measured from the original filing acceptance date. Provide the answer as a single real number in months. Give the exact value without rounding. Additionally, explain the policy basis for how the new date is determined in terms of how the extension is applied to the review clock rather than restarting it.",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- A New Drug Application (NDA) is granted Priority Review under the Prescription Drug User Fee Act (PDUFA).\n- The initial FDA action goal date is set at $6$ months from the date of filing acceptance, which is defined as $t = 0$ months.\n- At $t = 4$ months, the sponsor submits a major amendment.\n- The FDA extends the review clock by $3$ months.\n- Foundational Premise 1: Priority Review sets an initial action goal date at $6$ months from filing acceptance.\n- Foundational Premise 2: A major amendment permits the FDA to extend the review clock by up to $3$ months.\n- Required Output 1: Derive the new action goal date as a single time interval in months from the original filing acceptance date.\n- Required Output 2: Explain the policy basis for the calculation.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity against the established criteria.\n\n- **Scientific Grounding**: The problem is grounded in the field of regulatory science, a discipline concerned with the development and application of scientific principles to regulate products for public health. The PDUFA framework, Priority Review timelines, and rules for major amendments are established, verifiable facts governed by US law and FDA guidance. The premises are factually correct and based on real-world regulatory policy. The problem is therefore scientifically grounded within its domain.\n- **Well-Posed**: The problem is well-posed. It provides an initial condition (original goal date), a defined event (major amendment), and a specific consequence (extension duration). The question asks for a new goal date, which can be uniquely determined from the givens. There is no missing or contradictory information.\n- **Objectivity**: The problem is stated in precise, objective language, free of subjective claims or bias. It describes a procedural scenario based on established regulations.\n\nBased on this analysis, the problem does not violate any of the invalidity criteria. It is a factually sound, well-posed, and objective problem rooted in regulatory science.\n\n### Step 3: Verdict and Action\nThe problem is determined to be **valid**. A solution will be derived.\n\n### Solution Derivation\nThe problem requires the calculation of a new regulatory deadline based on a defined extension. This can be formalized using simple arithmetic applied to time intervals.\n\nLet $T_{initial}$ be the time interval corresponding to the initial action goal date, measured from the date of filing acceptance ($t=0$). From the problem statement, for a Priority Review, we have:\n$$T_{initial} = 6 \\text{ months}$$\n\nLet $\\Delta T_{ext}$ be the duration of the extension granted by the FDA following the submission of a major amendment. The problem states this extension is:\n$$\\Delta T_{ext} = 3 \\text{ months}$$\n\nThe problem also mentions that the major amendment was submitted at $t=4$ months. This information is the *trigger* for the extension but does not directly enter the calculation of the final deadline. The regulatory policy does not restart the review clock from the date of the amendment; rather, it *extends* the original review timeline.\n\nThe policy basis for this procedure is to maintain the integrity and structure of the initial review timeline while accommodating the need for additional review time. Resetting the clock would be unduly punitive and inefficient. An extension preserves the work already completed and appends the necessary extra time to the end of the original schedule. Thus, the new action goal date, $T_{new}$, is calculated by adding the extension period to the original action goal date.\n\nThe mathematical operation is a simple addition of these two time intervals:\n$$T_{new} = T_{initial} + \\Delta T_{ext}$$\n\nSubstituting the given values:\n$$T_{new} = 6 \\text{ months} + 3 \\text{ months}$$\n$$T_{new} = 9 \\text{ months}$$\n\nThe new action goal date is therefore $9$ months from the original filing acceptance date ($t=0$). This result is a direct consequence of applying a fixed-duration extension to a pre-existing deadline, a standard procedure in PDUFA-governed reviews.",
            "answer": "$$\\boxed{9}$$"
        },
        {
            "introduction": "Beyond procedural timelines, the core of a Priority Review request lies in substantiating the claim of \"significant improvement\" over available therapies. This becomes particularly complex in the era of precision medicine, where a drug's benefit may be concentrated in a specific, biomarker-defined subgroup. This practice problem  challenges you to weigh the evidence from such a scenario, integrating clinical trial data, the performance of a companion diagnostic, and patient-centric outcomes to make a principled regulatory assessment.",
            "id": "5052815",
            "problem": "A sponsor seeks Priority Review designation from the United States Food and Drug Administration (FDA) for an investigational therapy intended to treat a serious condition. Priority Review designation is granted when a marketing application would, if approved, be for a product that provides a significant improvement in safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition compared with available therapies. In a Phase $3$ randomized, controlled trial, the sponsor reports pronounced heterogeneity of treatment effect by a pre-specified biomarker, measured by a validated assay with known diagnostic characteristics.\n\nLet $S^{+}$ denote the biomarker-positive subgroup and $S^{-}$ the biomarker-negative subgroup. The biomarker prevalence in the indicated population is $\\pi = 0.20$. The primary clinical endpoint is a severe, morbid event with a Quality-Adjusted Life Year (QALY) loss per event of $L = 0.30$ over $12$ months. Serious Adverse Events (SAEs) attributable to the investigational therapy carry a QALY disutility of $D = 0.05$ per SAE. The following risks were observed over $12$ months:\n\n- In $S^{+}$: standard-of-care primary event risk $r_{0}^{+} = 0.50$, investigational therapy primary event risk $r_{1}^{+} = 0.20$; SAE risk increase attributable to investigational therapy $a^{+} = 0.02$.\n- In $S^{-}$: standard-of-care primary event risk $r_{0}^{-} = 0.25$, investigational therapy primary event risk $r_{1}^{-} = 0.23$; SAE risk increase attributable to investigational therapy $a^{-} = 0.04$.\n\nAssume the biomarker assay intended for a companion diagnostic has sensitivity $\\mathrm{Se} = 0.90$ and specificity $\\mathrm{Sp} = 0.95$. The sponsor proposes labeling that restricts treatment to patients who test positive per the companion diagnostic at the time of approval.\n\nFrom first principles, use the definitions of expected value $E[\\cdot]$, conditional average treatment effect as a risk difference $RD^{\\pm} = r_{1}^{\\pm} - r_{0}^{\\pm}$, Bayes’ theorem for Positive Predictive Value (PPV), and net QALY as the expected clinical benefit less expected disutility to evaluate how subgroup-specific large effects with overall modest average benefit should be weighed in claiming “significant improvement” for Priority Review. Which option best aligns with a principle-based regulatory assessment for Priority Review eligibility under the scenario described?\n\nA. The overall average benefit across the indicated population, computed without considering companion diagnostic targeting, is decisive; because the population-average net QALY gain is modest, Priority Review should not be granted.\n\nB. The decision should be based on the intended treated population after stratification by the companion diagnostic’s performance; if labeling is restricted to test-positive patients and the subgroup effect is pre-specified and biologically justified, the per-treated expected net QALY gain supports a claim of significant improvement despite a modest overall population-average.\n\nC. Any large effect in a subgroup, even if identified post hoc, justifies Priority Review because the subgroup benefit dominates the overall result.\n\nD. Relative risk or hazard ratio in the overall population alone determines Priority Review; if the overall hazard ratio is approximately $0.85$, that magnitude suffices to establish significant improvement.\n\nE. The absolute risk reduction of $0.30$ in $S^{+}$ alone is sufficient to claim significant improvement, regardless of SAE disutility or diagnostic misclassification, because the magnitude is clinically large.",
            "solution": "The problem statement is evaluated as valid. It is scientifically grounded in the principles of regulatory science, clinical trial analysis, and health economics. It is well-posed, providing all necessary quantitative information and clear definitions to perform a rigorous analysis. The scenario is a realistic representation of a common challenge in the development of targeted therapies.\n\nThe core of the problem is to assess whether an investigational therapy provides a \"significant improvement\" to warrant Priority Review, given a strong, pre-specified subgroup effect and a proposed patient selection strategy using a companion diagnostic. The assessment will be based on the concept of net Quality-Adjusted Life Year (QALY) gain.\n\nFirst, let us define the Net QALY Gain, $\\Delta QALY$, for a patient receiving the investigational therapy. This is the expected benefit from reducing the risk of the primary event, minus the expected disutility from the increased risk of Serious Adverse Events (SAEs).\n$$\n\\Delta QALY = L \\times (r_0 - r_1) - D \\times a\n$$\nwhere $L$ is the QALY loss per event, $r_0$ is the event risk on standard-of-care, $r_1$ is the event risk on investigational therapy, $D$ is the QALY disutility per SAE, and $a$ is the attributable SAE risk increase.\n\nThe problem provides the following data:\n-   Biomarker-positive subgroup ($S^{+}$): prevalence $\\pi = P(S^{+}) = 0.20$.\n-   Biomarker-negative subgroup ($S^{-}$): prevalence $1-\\pi = P(S^{-}) = 0.80$.\n-   QALY loss per event: $L = 0.30$.\n-   QALY disutility per SAE: $D = 0.05$.\n-   For $S^{+}$: $r_0^{+} = 0.50$, $r_1^{+} = 0.20$, $a^{+} = 0.02$.\n-   For $S^{-}$: $r_0^{-} = 0.25$, $r_1^{-} = 0.23$, $a^{-} = 0.04$.\n\nWe can now calculate the net QALY gain for each true biomarker subgroup.\n\nFor a patient in the $S^{+}$ subgroup, the net QALY gain is:\n$$\n\\Delta QALY^{+} = L \\times (r_{0}^{+} - r_{1}^{+}) - D \\times a^{+} = 0.30 \\times (0.50 - 0.20) - 0.05 \\times 0.02\n$$\n$$\n\\Delta QALY^{+} = 0.30 \\times 0.30 - 0.001 = 0.09 - 0.001 = 0.089\n$$\n\nFor a patient in the $S^{-}$ subgroup, the net QALY gain is:\n$$\n\\Delta QALY^{-} = L \\times (r_{0}^{-} - r_{1}^{-}) - D \\times a^{-} = 0.30 \\times (0.25 - 0.23) - 0.05 \\times 0.04\n$$\n$$\n\\Delta QALY^{-} = 0.30 \\times 0.02 - 0.002 = 0.006 - 0.002 = 0.004\n$$\nThe therapy provides a very large benefit to the $S^{+}$ subgroup but a minimal benefit to the $S^{-}$ subgroup.\n\nNext, we calculate the population-average net QALY gain, assuming everyone in the indicated population is treated, irrespective of biomarker status. This is the weighted average of the subgroup-specific gains.\n$$\nE[\\Delta QALY]_{\\text{overall}} = \\Delta QALY^{+} \\times P(S^{+}) + \\Delta QALY^{-} \\times P(S^{-})\n$$\n$$\nE[\\Delta QALY]_{\\text{overall}} = (0.089 \\times 0.20) + (0.004 \\times 0.80) = 0.0178 + 0.0032 = 0.021\n$$\nThis overall average benefit of $0.021$ QALYs is modest and, by itself, might not support a claim of \"significant improvement.\"\n\nHowever, the sponsor proposes to restrict treatment to patients who test positive ($T^{+}$) with a companion diagnostic. The performance of this assay is given by Sensitivity $\\mathrm{Se} = P(T^{+}|S^{+}) = 0.90$ and Specificity $\\mathrm{Sp} = P(T^{-}|S^{-}) = 0.95$. A regulatory assessment must evaluate the benefit in this intended-to-treat population.\n\nFirst, we find the probability of a patient testing positive, $P(T^{+})$, using the law of total probability:\n$$\nP(T^{+}) = P(T^{+}|S^{+})P(S^{+}) + P(T^{+}|S^{-})P(S^{-})\n$$\nWe know $P(T^{+}|S^{-}) = 1 - \\mathrm{Sp} = 1 - 0.95 = 0.05$.\n$$\nP(T^{+}) = (0.90 \\times 0.20) + (0.05 \\times 0.80) = 0.18 + 0.04 = 0.22\n$$\nThus, $22\\%$ of the population will test positive and be eligible for treatment under the proposed label.\n\nNow, we need to know the composition of this test-positive group. Using Bayes' theorem, we find the Positive Predictive Value (PPV), which is the probability that a test-positive patient is truly biomarker-positive:\n$$\nP(S^{+}|T^{+}) = \\frac{P(T^{+}|S^{+})P(S^{+})}{P(T^{+})} = \\frac{0.90 \\times 0.20}{0.22} = \\frac{0.18}{0.22} \\approx 0.8182\n$$\nThe probability that a test-positive patient is biomarker-negative (a false positive) is:\n$$\nP(S^{-}|T^{+}) = 1 - P(S^{+}|T^{+}) \\approx 1 - 0.8182 = 0.1818\n$$\n\nThe expected net QALY gain for a patient who is treated (i.e., conditional on testing positive) is the weighted average of the gains in the $S^{+}$ and $S^{-}$ subgroups, with weights given by the composition of the $T^{+}$ population:\n$$\nE[\\Delta QALY | T^{+}] = \\Delta QALY^{+} \\times P(S^{+}|T^{+}) + \\Delta QALY^{-} \\times P(S^{-}|T^{+})\n$$\n$$\nE[\\Delta QALY | T^{+}] \\approx (0.089 \\times 0.8182) + (0.004 \\times 0.1818)\n$$\n$$\nE[\\Delta QALY | T^{+}] \\approx 0.07282 + 0.00073 \\approx 0.07355\n$$\nThe expected net benefit in the intended-to-treat (test-positive) population is a QALY gain of approximately $0.074$. This is a substantial clinical benefit, far greater than the overall population average of $0.021$. This enrichment effect, achieved by using a pre-specified biomarker and a validated companion diagnostic, is the central argument for \"significant improvement.\"\n\nNow, we evaluate each option:\n\nA. The overall average benefit across the indicated population, computed without considering companion diagnostic targeting, is decisive; because the population-average net QALY gain is modest, Priority Review should not be granted.\nThis is **Incorrect**. Regulatory bodies like the FDA evaluate a product based on its proposed labeling and intended use. Ignoring the companion diagnostic strategy would be to assess the wrong risk-benefit profile. The modest overall average ($0.021$ QALYs) is not the relevant metric for a targeted therapy.\n\nB. The decision should be based on the intended treated population after stratification by the companion diagnostic’s performance; if labeling is restricted to test-positive patients and the subgroup effect is pre-specified and biologically justified, the per-treated expected net QALY gain supports a claim of significant improvement despite a modest overall population-average.\nThis is **Correct**. This option accurately reflects modern regulatory principles for precision medicine. It correctly identifies that the relevant population for assessment is the intended-to-treat (test-positive) group. It notes the importance of the subgroup being pre-specified, which gives the finding credibility. Our calculation confirms that the expected net QALY gain in this population ($0.074$) is substantial and could support a claim of \"significant improvement\" in contrast to the modest overall average.\n\nC. Any large effect in a subgroup, even if identified post hoc, justifies Priority Review because the subgroup benefit dominates the overall result.\nThis is **Incorrect**. The credibility of a subgroup analysis is paramount. Effects discovered in post-hoc, exploratory analyses are viewed with skepticism due to the high risk of false positives from multiple testing. The problem explicitly states the biomarker was \"pre-specified,\" which is a key strength. Claiming that a post-hoc finding would carry the same weight is contrary to established principles of statistical inference in clinical trials.\n\nD. Relative risk or hazard ratio in the overall population alone determines Priority Review; if the overall hazard ratio is approximately $0.85$, that magnitude suffices to establish significant improvement.\nThis is **Incorrect**. First, regulatory decisions are based on the totality of evidence, not a single metric like relative risk (RR). Absolute risk reduction and safety are also critical. Second, it focuses on the \"overall population,\" which, as argued for option A, is not the relevant population for this targeted therapy. We can calculate the overall RR: $R_0 = 0.5(0.2) + 0.25(0.8) = 0.3$ and $R_1 = 0.2(0.2) + 0.23(0.8) = 0.224$. The overall $RR = 0.224/0.30 \\approx 0.747$. The claim that an overall RR \"alone determines\" the decision is a fundamental flaw.\n\nE. The absolute risk reduction of $0.30$ in $S^{+}$ alone is sufficient to claim significant improvement, regardless of SAE disutility or diagnostic misclassification, because the magnitude is clinically large.\nThis is **Incorrect**. A principle-based assessment cannot be \"regardless\" of key factors. The SAE disutility is essential for a complete risk-benefit analysis. More importantly, it is not possible to perfectly treat only the $S^{+}$ population. The \"diagnostic misclassification\" is a practical reality that reduces the average benefit in the treated population due to the inclusion of false positives. Ignoring these factors leads to an overestimation of the real-world benefit and is not a sound basis for a regulatory decision.\n\nTherefore, Option B provides the most accurate and principled description of how such a case would be evaluated for Priority Review.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The strategic value of an accelerated review extends into the financial realm, where time directly translates to value. The Priority Review Voucher (PRV) market makes this explicit, treating the 4-month time savings as a tradable asset. This final exercise  asks you to step into the role of a biopharma strategist and develop a quantitative decision rule for whether to redeem a PRV on an internal asset or sell it, based on principles of financial valuation and operational risk.",
            "id": "5052864",
            "problem": "A sponsor in translational medicine holds a Priority Review Voucher (PRV) that guarantees the United States Food and Drug Administration (FDA) will target a $6$-month review for a single application. The sponsor must decide whether to redeem the PRV on its own lead asset or sell the PRV to a third party. Assume the following scientifically grounded and widely used financial modeling facts:\n\n- Under discounted cash flow with continuous compounding, the present value of a cash flow stream that begins at time $t$ is multiplicatively reduced by $\\exp(-r t)$, where $r$ is the annual cost of capital.\n- The internal pipeline asset has an expected at-approval present value $V$ (measured at the approval date), which already incorporates development risk and market uncertainty conditional on approval. If approval occurs at time $t$ from today, the present value today is $V \\exp(-r t)$.\n- Without a PRV, the sponsor expects a standard review time of $10$ months. With a PRV, the sponsor can target a $6$-month review. Measure all times in years: $T_{\\text{std}} = \\frac{10}{12}$ and $T_{\\text{PRV}} = \\frac{6}{12} = 0.5$.\n- Operational capacity affects the ability to actually achieve the $6$-month review. Let $p \\in [0,1]$ denote the probability that the sponsor’s organization can meet the operational demands necessary to realize the accelerated $6$-month review when redeeming the PRV. If the sponsor fails to meet these demands (with probability $1-p$), the realized review duration reverts to the standard $10$-month timeline.\n\nA third party offers to buy the PRV for a sale price $S$, paid immediately at time $0$. Using only the fundamentals stated above, derive a decision rule based on indifference: find the sale price $S^{*}$ at which the sponsor is indifferent between redeeming the PRV itself versus selling it. Express $S^{*}$ as a single closed-form analytic expression in terms of $V$, $r$, and $p$, using continuous compounding and the time parameters specified above. Express your answer in the same currency units as $V$. No numerical rounding is required.",
            "solution": "The problem asks for the indifference sale price $S^{*}$ of a Priority Review Voucher (PRV). This price is defined as the amount $S$ for which a sponsor is indifferent between two courses of action:\n1.  Selling the PRV for price $S$ and having their own asset undergo a standard review.\n2.  Redeeming the PRV for their own asset, forgoing the sale price $S$, and targeting an accelerated review.\n\nTo find $S^{*}$, we must first determine the expected present value (PV) of each course of action. The indifference point occurs when these two present values are equal. We will use the provided definitions and variables.\n\nLet $V$ be the at-approval present value of the asset.\nLet $r$ be the annual cost of capital (discount rate).\nThe present value today of an asset approved at a future time $t$ is given by $V \\exp(-rt)$.\nThe standard review time is $T_{\\text{std}} = \\frac{10}{12}$ years $= \\frac{5}{6}$ years.\nThe PRV-accelerated review time is $T_{\\text{PRV}} = \\frac{6}{12}$ years $= 0.5$ years.\nLet $p$ be the probability that the sponsor successfully achieves the $T_{\\text{PRV}}$ timeline when redeeming the PRV.\nThe probability of failing to achieve the accelerated timeline, thus reverting to $T_{\\text{std}}$, is $1-p$.\n\nLet's formalize the present value of each scenario.\n\n**Scenario 1: Sell the PRV**\nIf the sponsor sells the PRV, they receive a cash payment of $S$ at time $t=0$. This payment is already at its present value. Additionally, their own asset proceeds through the standard review process, with an expected approval at time $T_{\\text{std}}$. The present value of the asset is therefore discounted over the time $T_{\\text{std}}$.\nThe total present value of this scenario, $PV_{\\text{sell}}$, is the sum of the sale price and the discounted value of the asset:\n$$PV_{\\text{sell}} = S + V \\exp(-r T_{\\text{std}})$$\n\n**Scenario 2: Redeem the PRV**\nIf the sponsor redeems the PRV, they do not receive a cash payment. Instead, they use the voucher on their own asset. The outcome is probabilistic.\n- With probability $p$, the accelerated review is successful, and approval occurs at time $T_{\\text{PRV}}$. The present value of the asset in this case is $V \\exp(-r T_{\\text{PRV}})$.\n- With probability $1-p$, the accelerated review is not operationally met, and the review duration reverts to the standard time $T_{\\text{std}}$. The present value of the asset in this case is $V \\exp(-r T_{\\text{std}})$.\n\nThe total expected present value of this scenario, $PV_{\\text{redeem}}$, is the probability-weighted average of the two possible outcomes:\n$$PV_{\\text{redeem}} = p \\cdot \\left( V \\exp(-r T_{\\text{PRV}}) \\right) + (1-p) \\cdot \\left( V \\exp(-r T_{\\text{std}}) \\right)$$\n\n**Indifference Condition**\nThe indifference sale price $S^{*}$ is the value of $S$ that makes the two scenarios equally attractive, i.e., $PV_{\\text{sell}} = PV_{\\text{redeem}}$.\nSetting the two expressions equal, with $S=S^{*}$:\n$$S^{*} + V \\exp(-r T_{\\text{std}}) = p V \\exp(-r T_{\\text{PRV}}) + (1-p) V \\exp(-r T_{\\text{std}})$$\n\nNow, we solve for $S^{*}$ by isolating it on one side of the equation.\nFirst, expand the term $(1-p) V \\exp(-r T_{\\text{std}})$:\n$$S^{*} + V \\exp(-r T_{\\text{std}}) = p V \\exp(-r T_{\\text{PRV}}) + V \\exp(-r T_{\\text{std}}) - p V \\exp(-r T_{\\text{std}})$$\n\nSubtract the term $V \\exp(-r T_{\\text{std}})$ from both sides:\n$$S^{*} = p V \\exp(-r T_{\\text{PRV}}) - p V \\exp(-r T_{\\text{std}})$$\n\nFactor out the common terms $p$ and $V$:\n$$S^{*} = p V \\left( \\exp(-r T_{\\text{PRV}}) - \\exp(-r T_{\\text{std}}) \\right)$$\n\nThis expression represents the expected incremental value generated by using the PRV. The term in the parentheses is the increase in present value from accelerating the approval date. This value is then multiplied by the probability $p$ of actually realizing this acceleration.\n\nFinally, we substitute the given time values $T_{\\text{PRV}} = 0.5$ and $T_{\\text{std}} = \\frac{10}{12} = \\frac{5}{6}$:\n$$S^{*} = p V \\left( \\exp(-r \\cdot 0.5) - \\exp(-r \\cdot \\frac{5}{6}) \\right)$$\nThis is the final closed-form analytic expression for the indifference sale price $S^{*}$ in terms of $V$, $r$, and $p$.",
            "answer": "$$\\boxed{p V \\left( \\exp(-0.5 r) - \\exp(-\\frac{5}{6} r) \\right)}$$"
        }
    ]
}